

Iran J Nucl Med. 2023;31(1):105-108 [Serial No. 60]

Homepage: https://irjnm.tums.ac.ir/

We report a patient with locally invasive metastatic castration resistant prostate

adenocarcinoma, which had massive invasion to the bladder and caused frequent

gross hematuria. The patient had received more than 10 units of packed cell at the time he was referred for $[^{177}Lu]Lu-PSMA-617$ therapy, but despite frequent

transfusions his serum hemoglobin level had been under 8 g/dl most of the time.

He had received first generation androgen deprivation therapy (ADT) from 3 years previously and the second generation since 1 year ago and had undergone

multiple procedures for cessation of hematuria, such as multiple cystoscopies,

bladder irrigations and angioembolizations. We performed [99mTc]Tc-PSMA

whole body and SPECT/CT scan, which demonstrated a large PSMA avid prostate

mass invading the urinary bladder wall. All components of the locally invasive

tumor were present demonstrating high PSMA avidity, so he was scheduled for

[¹⁷⁷Lu]Lu-PSMA-617 therapy. One week after the diagnostic scan, therapeutic dose of [¹⁷⁷Lu]Lu-PSMA-617 was administered. The patient reported no hematuria 4 days after the [¹⁷⁷Lu]Lu-PSMA-617 administration. In the follow up,

no recurrent hematuria was reported, too. The PSA level also declined from 40.5

Case Report

Dramatic cessation of gross sustained treatment resistant hematuria after [¹⁷⁷Lu]Lu-PSMA-617 therapy: A case report

Hamid Reza Ghorbani¹, Salman Soltani¹, Vahid Roshanravan², Kamran Aryana², Atena Aghaee²

¹Kidney Transplant Research Center, Mashhad University of Medical Sciences, Mashhad, Iran ²Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

ABSTRACT

Article History: Received: 22 June 2022 Revised: 23 October 2022 Accepted: 26 October 2022 Published Online: 05 November 2022

Keyword:CastrationresistantprostateadenocarcinomaAndrogen deprivation therapyHematuria[¹⁷⁷Lu]Lu-PSMA-617

*Corresponding Author: Atena Aghaee, MD Address: Nuclear Medicine Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Email: aghaeeat@mums.ac.ir

Use your device to scan and read the article online

How to cite this article: Ghorbani HR, Soltani S, Roshanravan V, Aryana K, Aghaee A. Dramatic cessation of gross sustained treatment resistant hematuria after [¹⁷⁷Lu]Lu-PSMA-617 therapy: A case report. Iran J Nucl Med. 2023;31(1):105-108.

ng/ml to 18.7 ng/ml, 1 month after the first treatment.



Copyright © 2023 The Authors. Published by Tehran University of Medical Sciences.

This work is published as an open access article distributed under the terms of the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by-nc/4). Non-commercial uses of the work are permitted, provided the original work is properly cited.

CASE PRESENTATION

We report a 78 years old man, with history of biopsy proven prostatic adenocarcinoma (Gleason score 4+5) since three years previously, who was diagnosed as a case of locally invasive metastatic castration resistant prostate adenocarcinoma, which had massive invasion to the bladder wall, presenting with frequent gross hematuria. The patient had received more than 10 units of pack cell at the time he was referred for [¹⁷⁷Lu]Lu-PSMA-617 therapy, but despite frequent transfusions his hemoglobin level remained under 8 g/dl most of the time.

He had received first generation ADT from 3 and subsequently second generation ADT from 1 year

ago and had undergone multiple procedures for cessation of hematuria, such as multiple cystoscopies, bladder irrigations and angioembolizations attempts at the urology department.

His bone scan showed widespread skeletal metastasis and his serum PSA value was 40.5 ng/ml. We performed [^{99m}Tc]Tc-PSMA whole body and SPECT/CT scan to confirm the PSA avidity of the metastatic sites. PSMA scan showed multiple PSMA avid skeletal and abdomino-pelvic lymph node metastasis, as well as intense uptake in the prostatic bed (Figure 1).




Fig 1. Whole body images of [99mTc]Tc-PSMA scan showing multiple PSMA avid metastasis throughout the body

Pelvic [^{99m}Tc]Tc-PSMA SPECT/CT scan demonstrated a large PSMA avid prostate mass with evidence of massive invasion to the bladder wall which seemed responsible for severe sustained gross hematuria (Figures 2 and 3). All components of the locally invasive tumor showed high PSMA avidity, so he was scheduled for $[^{177}Lu]Lu$ -PSMA-617 therapy.




Fig 2. Pelvic SPECT/CT images demonstrate a large PSMA avid prostatic mass




Fig 3. Pelvic SPECT/CT images demonstrate invasion to the posterior bladder wall

The laboratory data including serum CBC, LFT and serum creatinine level were within normal limits, except for severe anemia (hemoglobin 8 g/dl at the time of first visit). The therapeutic dose was administered following packed cell transfusion. After IV hydration by 500 cc normal saline infusion, 210 mCi of [¹⁷⁷Lu]Lu-PSMA-617 was

injected and whole body scan was also performed after 24 hours. The scan showed excellent uptake in the metastatic sites, as well as the prostate tumor and also the intra-vesical component of the tumor (Figure 4).




Fig 4. Whole body post ablation scan 24 hour after administration of 210mCi, [¹⁷⁷Lu]Lu-PSMA-617, shows tracer avidity in the widespread metastatic sites

Surprisingly, the patient reported complete cessation of gross hematuria 4 days after [¹⁷⁷Lu]Lu-PSMA-617 therapy and in the subsequent follow ups. Serum PSA declined from 40.5 ng/ml to 18.7 ng/ml, 1 month after treatment.

DISCUSSION

[¹⁷⁷Lu]Lu-PSMA-617 therapy is currently the treatment of choice for metastatic castration resistant prostate cancer patients. Many trials has been conducted to evaluate the efficacy and safety of this treatment modality [1, 2]. The treatment with [¹⁷⁷Lu]Lu-PSMA-617 has been demonstrated to be a safe and effective method for the therapy of castration-resistant prostate cancer patients. The fractionation regime and therapeutic doses that enables the longest duration of tumor control and overall progression free survival, need to be evaluated in future studies [3, 4].

CONCLUSION

Our case introduces an interesting therapeutic effect of [¹⁷⁷Lu]Lu-PSMA-617, leading to cessation

of gross hematuria just a few days after administration of the 1st therapeutic dose.

REFERENCES

- Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Kumar AR, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun;19(6):825-833.
- Rahbar K, Bodei L, Morris MJ. Is the vision of radioligand therapy for prostate cancer becoming a reality? An overview of the phase III VISION trial and its importance for the future of theranostics. J Nucl Med. 2019 Nov;60(11):1504-1506.
- Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, Aygün A, Karayel E, Pehlivanoğlu H, Selçuk NA. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68.
- Hofman MS, Emmett L, Violet J, Zhang AY, Lawrence NJ, Stockler M, Francis RJ, Iravani A, Williams S, Azad A, Martin A, McJannett M, Davis ID. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castrationresistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019 Nov;124 Suppl 1:5-13.